Clinical Trials Logo

Embolism and Thrombosis clinical trials

View clinical trials related to Embolism and Thrombosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05481242 Active, not recruiting - Clinical trials for Pulmonary Embolism and Thrombosis

An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients

Start date: January 1, 2011
Phase:
Study type: Observational

This multi-center retrospective study collected clinical, laboratory, and CT pulmonary angiography parameters with acute pulmonary embolism patients from admission to predict adverse outcomes within 30 days after admission into hospital.

NCT ID: NCT04632641 Active, not recruiting - Atrial Fibrillation Clinical Trials

Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial

SAFE-VEIN
Start date: April 23, 2021
Phase: N/A
Study type: Interventional

Primary objective: To compare the safety and efficacy of closure strategies post venous access procedures. Hypothesis: We anticipate that the use of a venous closure device will decrease the time to hemostasis (TTH), time to ambulation (TTA) and time to discharge (TTD) compared to conventional methods of closure following venous access procedure.

NCT ID: NCT04437303 Active, not recruiting - Stroke Clinical Trials

Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

Start date: November 25, 2020
Phase: Phase 4
Study type: Interventional

Transcatheter aortic valve implantation (TAVI) is a rapidly growing treatment option for patients with aortic valve stenosis. Stroke is a feared complication of TAVI, with an incidence of around 4-5% in the first 30 days. Up to 50% of patients undergoing TAVI have an indication for oral anticoagulants (OAC) mostly for atrial fibrillation. OAC use during TAVI could increase bleeding complications, but interruption during TAVI may increase the risk for thromboembolic events (i.e. stroke, systemic embolism, myocardial infarction). Recent observational data suggest that periprocedural continuation of OAC is safe and might decrease the risk of stroke. Beside the potential reduction of thromboembolic events, continuation of OAC is associated with an evident clinical ancillary benefit for patients and staff. Since periprocedural OAC interruption not infrequently leads to misunderstanding and potentially dangerous situations, when patients are not properly informed before hospital admission or may experience difficulties with the interruption regimen. Hypothesis: Periprocedural continuation of oral anticoagulants is safe and might decrease thromboembolic complications without an increase in bleeding complications at 30 days

NCT ID: NCT04375982 Active, not recruiting - Inflammation Clinical Trials

Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests

NOVEL-3
Start date: April 20, 2020
Phase: N/A
Study type: Interventional

A Multicenter Study Conducted to Evaluate the Agreement between Fingerstick Whole Blood, Venous Whole Blood and Plasma Determined on the LumiraDx Point of Care D-Dimer and Point of Care CRP Tests to Results on the Reference Analyzer